Knuff & Co LLC Acquires New Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Knuff & Co. LLC acquired 16,438 shares of Bristol Myers Squibb during the second quarter, valued at approximately $947,000. Institutional investors collectively own 76.41% of the company.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. The company issued fiscal 2026 EPS guidance of $6.75–$7.00.
• The stock recently traded at $67.59, up 2.3%, and pays a quarterly dividend of $0.63, representing a 3.7% annual yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $66.06, though several firms raised targets to $73–$75.

Knuff & Co LLC bought a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 16,438 shares of the biopharmaceutical company's stock, valued at approximately $947,000.

Several other hedge funds have also modified their holdings of the company. Swiss RE Ltd. purchased a new position in shares of Bristol Myers Squibb in the 4th quarter worth approximately $25,000. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb during the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. boosted its stake in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. Bayban acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in Bristol Myers Squibb in the fourth quarter worth $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Up 2.3%

Shares of NYSE:BMY opened at $67.59 on Thursday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The stock has a market cap of $138.06 billion, a price-to-earnings ratio of 14.89, a PEG ratio of 0.17 and a beta of 0.22. The business has a 50-day moving average price of $60.18 and a 200-day moving average price of $59.24.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the prior year, the firm earned $1.46 earnings per share. Bristol Myers Squibb's revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio is 55.51%.

Analysts Set New Price Targets

Several analysts have recently commented on BMY shares. Cantor Fitzgerald reiterated a "neutral" rating and set a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Guggenheim reaffirmed a "buy" rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Sanford C. Bernstein raised Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a report on Wednesday, August 5th. Argus upgraded Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price target on the stock in a research note on Wednesday, August 5th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an "overweight" rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb currently has an average rating of "Moderate Buy" and an average price target of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source